Sphera Funds Management LTD. Takes $3.71 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Sphera Funds Management LTD. bought a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 197,550 shares of the biotechnology company's stock, valued at approximately $3,714,000. Sphera Funds Management LTD. owned approximately 0.16% of Arrowhead Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also made changes to their positions in ARWR. R Squared Ltd bought a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth about $38,000. Van ECK Associates Corp lifted its holdings in Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after buying an additional 1,250 shares in the last quarter. KBC Group NV boosted its position in Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock valued at $98,000 after buying an additional 1,644 shares during the last quarter. Envestnet Portfolio Solutions Inc. bought a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth $190,000. Finally, First Citizens Bank & Trust Co. acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at $205,000. 62.61% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Chardan Capital reissued a "buy" rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. StockNews.com raised shares of Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, May 14th. HC Wainwright reissued a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday. B. Riley reissued a "buy" rating and issued a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. Finally, Citigroup dropped their target price on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, Arrowhead Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $42.13.

Arrowhead Pharmaceuticals Stock Down 6.5%

Shares of ARWR traded down $1.06 during mid-day trading on Wednesday, hitting $15.23. 788,731 shares of the company's stock were exchanged, compared to its average volume of 1,488,780. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $30.41. The company has a market cap of $2.10 billion, a PE ratio of -2.95 and a beta of 0.89. The company has a 50-day simple moving average of $13.33 and a 200 day simple moving average of $17.75.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, topping the consensus estimate of ($0.06) by $2.81. The business had revenue of $542.71 million for the quarter, compared to analyst estimates of $116.27 million. During the same quarter in the previous year, the company posted ($1.02) EPS. On average, research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 51,425 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $15.07, for a total transaction of $774,974.75. Following the completion of the sale, the chief executive officer now owns 4,062,377 shares of the company's stock, valued at $61,220,021.39. This trade represents a 1.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 275,880 shares of company stock valued at $4,034,037 in the last three months. 4.30% of the stock is currently owned by corporate insiders.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.